- Home
- FATE vs IMRX Comparison
FATE vs IMRX Comparison
Compare FATE & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FATE
- IMRX
- Stock Information
- Founded
- FATE 2007
- IMRX 2008
- Country
- FATE United States
- IMRX United States
- Employees
- FATE N/A
- IMRX 54
- Industry
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- IMRX Biotechnology: Pharmaceutical Preparations
- Sector
- FATE Health Care
- IMRX Health Care
- Exchange
- FATE Nasdaq
- IMRX Nasdaq
- Market Cap
- FATE 177.7M
- IMRX 145.7M
- IPO Year
- FATE 2013
- IMRX 2021
- Fundamental
- Price
- FATE $1.14
- IMRX $4.24
- Analyst Decision
- FATE Hold
- IMRX Strong Buy
- Analyst Count
- FATE 7
- IMRX 4
- Target Price
- FATE $3.83
- IMRX $13.25
- AVG Volume (30 Days)
- FATE 1.9M
- IMRX 3.1M
- Earning Date
- FATE 08-12-2025
- IMRX 08-05-2025
- Dividend Yield
- FATE N/A
- IMRX N/A
- EPS Growth
- FATE N/A
- IMRX N/A
- EPS
- FATE N/A
- IMRX N/A
- Revenue
- FATE $13,335,000.00
- IMRX N/A
- Revenue This Year
- FATE N/A
- IMRX N/A
- Revenue Next Year
- FATE N/A
- IMRX N/A
- P/E Ratio
- FATE N/A
- IMRX N/A
- Revenue Growth
- FATE 105.85
- IMRX N/A
- 52 Week Low
- FATE $0.66
- IMRX $1.00
- 52 Week High
- FATE $5.92
- IMRX $4.60
- Technical
- Relative Strength Index (RSI)
- FATE 46.69
- IMRX 77.22
- Support Level
- FATE $1.05
- IMRX $3.31
- Resistance Level
- FATE $1.18
- IMRX $4.60
- Average True Range (ATR)
- FATE 0.08
- IMRX 0.43
- MACD
- FATE -0.00
- IMRX 0.12
- Stochastic Oscillator
- FATE 54.76
- IMRX 96.10
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.